Can new drug cocktails beat back Hard-to-Treat leukemia?

NCT ID NCT06265545

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial is testing several different drug combinations to find the best approach for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The study compares the effectiveness and safety of these salvage therapies, aiming to improve remission rates and survival. It includes adults with refractory or relapsed AML (excluding a subtype called APL) and measures outcomes like overall response and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multiple drug combinations including ivosidenib, venetoclax, gilteritinib, homoharringtonine, cytarabine, anthracyclines, azacitidine, lisaftoclax, and other investigational agents
What this could lead to: If successful, this could identify more effective treatment regimens for patients with hard-to-treat AML, potentially improving remission rates and survival.
What could go wrong: This is an early-stage platform trial, and the various drug combinations may not all prove safe or effective. There is also risk of significant side effects from intensive chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML REFRACTORY RELAPSED

Contacts and locations

Locations

Blood Hospital
RECRUITING

Tianjin, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.